<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02110446</url>
  </required_header>
  <id_info>
    <org_study_id>102-2481A</org_study_id>
    <nct_id>NCT02110446</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy and the Mechanism of Chinese Herbal Formula SS-1 for Sjögren's Syndrome</brief_title>
  <acronym>SS-1</acronym>
  <official_title>Evaluation of the Efficacy and the Mechanism of Chinese Herbal Formula SS-1 for Sjögren's Syndrome - A Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chang Gung University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Science Council, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>China Medical University, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>China Medical University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of Chinese herbal medicine (SS-1) for the Sjögren's syndrome (SJS)&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigators take a randomized, double-blinded, placebo-controlled, cross-over design&#xD;
      clinical trial to evaluate the effect of Chinese herbal medicine (SS-1) on the regulation of&#xD;
      oxidative-related cytokines and the antioxidant capacity for the Sjögren's syndrome (SJS)&#xD;
      patients. Through the oxidative stress reduction, the quality of life and clinical&#xD;
      manifestation will be improved. Investigators will also use a SJS cell model to elucidate the&#xD;
      antioxidant mechanism of SS-1.&#xD;
&#xD;
      The SJS patients in this clinical trial will be screened and be referred from the out-patient&#xD;
      department (OPD) of the Rheumatology Department of Chang Gung Memorial Hospital. The patients&#xD;
      will be divided into two groups (A and B) at random and all of them keep the routine&#xD;
      treatment in the rheumatology OPD. Group A patients will receive 12 weeks SS-1 treatment&#xD;
      first and stop the SS-1 for 4 weeks to enter the wash-out phase, and then receive 12 weeks&#xD;
      placebo treatment after the wash-out phase. Group B patients receive 12 weeks placebo first&#xD;
      and stop the placebo treatment for 4 weeks to enter the wash-out phase, and then receive 12&#xD;
      weeks SS-1 treatment after the wash-out phase. SS-1 is composed of the powder of Gan-Lu-Yin,&#xD;
      Sang-Ju-Yin and Xuefu-Zhuyu-Decoction with the ratio of 2:1:1 and the placebo is composed&#xD;
      with corn starch, pigment and 1/100 SS-1. Patients in both groups take 6 gram of experiment&#xD;
      medicine three times per day. Investigators plan to evaluate the associated parameters at the&#xD;
      time just before treatment (V1), after treatment for 12 weeks (V2), at the end of wash-out&#xD;
      phase (V3) and when the crossover treatment is completed (V4). Investigators use EULAR&#xD;
      Sjogren's syndrome patient reported index, ocular surface disease index and SJS symptom&#xD;
      questionnaire for clinical evaluation, and use the SF-36 for quality of life. And&#xD;
      investigators use the schirmer's test, salivary scintigraphy, oxidative stress marker and&#xD;
      related cytokine for objective observation.&#xD;
&#xD;
      Expected Results:&#xD;
&#xD;
        1. SS-1 may improve the clinical manifestation and quality of life for the patients with&#xD;
           Sjögren's syndrome&#xD;
&#xD;
        2. To evaluate the effect of the Chinese medicine on the tongue diagnosis before and after&#xD;
           treatment.&#xD;
&#xD;
        3. SS-1 may reduce the oxidative stress (8-OHdG and mtDNA 4977 bp deletion) and elevate the&#xD;
           antioxidant capacity (TAC, GSH, mtDNA copy number, SOD, GPX, CAT).&#xD;
&#xD;
        4. SS-1 may have the regulatory effect on cytokine secretion and immune function.&#xD;
&#xD;
        5. SS-1 may have the capacity of reducing the oxidative stress, elevating the antioxidant&#xD;
           capacity and regulating the immune response in the model of submaxillary salivary gland&#xD;
           cell line with the induction of IFN-γand IFN-α.&#xD;
&#xD;
        6. Identification of the single herb in the SS-1 mixture that regulates oxidative stress&#xD;
           and cytokine in the model of submaxillary salivary gland cell line, and set up of the&#xD;
           Chinese herbs screen platform for Sjögren's syndrome.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular surface disease index (OSDI)</measure>
    <time_frame>7 months</time_frame>
    <description>SS-1 may improve the subjective observation of dry eye.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EULAR Sjogren's syndrome patient reported index (ESSPRI)</measure>
    <time_frame>7 months</time_frame>
    <description>SS-1 may improve the subjective sensation of dry, pain and fatigue.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SJS symptoms Questionnaire</measure>
    <time_frame>7 months</time_frame>
    <description>SS-1 may improve the subjective sensation of dry month.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Schirmer's test</measure>
    <time_frame>7 months</time_frame>
    <description>SS-1 may improve the objective observation of dry eye.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Salivary scintigraphy</measure>
    <time_frame>7 months</time_frame>
    <description>SS-1 may improve the objective observation of dry month.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oxidative stress and antioxidant capacity</measure>
    <time_frame>7 months</time_frame>
    <description>SS-1 may reduce the oxidative stress and elevate the antioxidant capacity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (SF-36)</measure>
    <time_frame>7 months</time_frame>
    <description>SS-1 may improve the subjective observation of quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regulatory effect on cytokine</measure>
    <time_frame>7 months</time_frame>
    <description>SS-1 may have the regulatory effect on cytokine secretion and immune function.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse effect (AE) and Adverse drug reaction(ADR)</measure>
    <time_frame>7 months</time_frame>
    <description>Monitor the Adverse effect (AE) and Adverse drug reaction(ADR) during the SS-1 trial.</description>
  </other_outcome>
  <other_outcome>
    <measure>Liver, Kidney and Blood function monitor</measure>
    <time_frame>7 months</time_frame>
    <description>Monitor the Liver, Kidney and Blood function (RBC, WBC, Hb, PLT, AST, ALT, BUN, Cre) of patient during the SS-1 trial.</description>
  </other_outcome>
  <other_outcome>
    <measure>Traditional Chinese medicine (TCM) tongue diagnosis</measure>
    <time_frame>7 months</time_frame>
    <description>To evaluate the effect of the SS-1 on the TCM tongue diagnosis before and after treatment.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Sjögren's Syndrome</condition>
  <arm_group>
    <arm_group_label>SS-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SS-1 is composed of the powder of Gan-Lu-Yin, Sang-Ju-Yin and Xuefu-Zhuyu-Decoction with the ratio of 2:1:1. Patients take 6 gram of experiment medicine three times per day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo is composed of corn starch, pigment and minimal dose of 1% SS-1. Patients take 6 gram of experiment medicine three times per day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SS-1</intervention_name>
    <description>The patients will be divided into two groups (A and B) at random and all of them keep the routine treatment in the rheumatology OPD. Group A patients will receive 12 weeks SS-1 treatment first, and then stop the SS-1 for 4 weeks for wash-out phase, and then receive 12weeks placebo treatment. Group B patients receive 12 weeks placebo first, and then stop the placebo treatment for 4 weeks for wash-out phase, and then receive 12weeks SS-1 treatment.&#xD;
SS-1 is composed of 3 traditional Chinese herbal formula: Gan-Lu-Yin, Sang-Ju-Yin and Xuefu-Zhuyu-Decoction with the ratio of 2:1:1. The placebo is composed with corn starch, pigment and minimal dose of 1% SS-1. Patients in both groups take 6 gram of SS-1/Placebo three times per day.</description>
    <arm_group_label>SS-1</arm_group_label>
    <other_name>Gan-Lu-Yin, Sang-Ju-Yin and Xuefu-Zhuyu-Decoction</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The placebo is composed of corn starch, pigment and minimal dose of 1% SS-1. Patients take 6 gram of experiment medicine three times per day.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>1% SS-1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Primary or Secondary Sjögren's syndrome patient&#xD;
&#xD;
          -  Age from 20 to 75 year old, male or female patient&#xD;
&#xD;
          -  Fit the criteria of 2002 year American-European classification&#xD;
&#xD;
          -  If the subject took Cyclosporine, Cevimeline, Pilocarpine, Rituximab or other&#xD;
             biological agent before enter into our study, the subject need to stop these drugs for&#xD;
             one month&#xD;
&#xD;
          -  If the subject took Gan-Lu-Yin, Sang- Ju-Yin or Xuefu-Zhuyu-Decoction before enter&#xD;
             into our study, the subject need to stop these drugs for one month&#xD;
&#xD;
          -  Secondary Sjögren's syndrome patient:&#xD;
&#xD;
               -  Stable treatment: Steroid (≦10mg/d) and fixed hydroxychloroquine dose before 3&#xD;
                  months enrolled&#xD;
&#xD;
               -  No abnormal change of immunology, liver, kidney, and blood function&#xD;
&#xD;
               -  No major life threatened condition&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Alcohol abuse, DM (Glucose PC&gt;200mg/dL) and major life threatened condition&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  Abnormal liver and kidney function&#xD;
&#xD;
          -  Forbid steroid pulse therapy before 3 months enrolled into our study, and forbid the&#xD;
             Chinese herbal medicine except SS-1&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hen-Hong Chang, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang Gung University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hen-Hong Chang, M.D., Ph.D.</last_name>
    <phone>+886-3196200</phone>
    <phone_ext>2677</phone_ext>
    <email>tcmchh55@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ching-Mao Chang, M.D.</last_name>
    <phone>+886-3196200</phone>
    <phone_ext>2676</phone_ext>
    <email>magicbjp@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Center for Traditional Chinese Medicine, Taoyuan Chang Gung Memorial Hospital</name>
      <address>
        <city>Gueishan Township</city>
        <state>Taoyuan</state>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hen-Hong Chang, M.D., Ph.D.</last_name>
      <phone>+886-3196200</phone>
      <phone_ext>2677</phone_ext>
      <email>tcmchh55@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ching-Mao Chang, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yau-Huei Wei, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jr-Rung Lin, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kuang-Hui Yu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shue-Fen Luo, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hen-Hong Chang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yeong-Jian Jan Wu Jan, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ji-Yih Chen, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yao-Fan Fang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>April 1, 2014</study_first_submitted>
  <study_first_submitted_qc>April 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2014</study_first_posted>
  <last_update_submitted>January 31, 2016</last_update_submitted>
  <last_update_submitted_qc>January 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sjögren's syndrome</keyword>
  <keyword>SS-1</keyword>
  <keyword>Gan-Lu-Yin</keyword>
  <keyword>Sang-Ju-Yin</keyword>
  <keyword>Xuefu-Zhuyu-Decoction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sjogren's Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

